This website has been commissioned by Ipsen Pharmaceuticals Ltd. and is intended for Irish Healthcare Professionals. If you are not a Healthcare Professional, please click here.
Adverse event reporting information is available at the bottom of this webpage.

Dysport® (Clostridium botulinum type A toxin-haemagglutinin complex)
Dysport<sup>®</sup> (<em>Clostridium botulinum</em> type A toxin-haemagglutinin complex)

Paediatric spasticity and cerebral palsy: What it means for your child

Paediatric Spasticity File
36 pages

This booklet is designed as a guide for parents and/or caregivers of children being considered for treatment with botulinum toxin for spasticity. It provides information abour cerebral palsy, the tests that may be required, treatment options and where to find further support and advice.

DYS-IE-000963 | August 2025

Paediatric spasticity and cerebral palsy: What it means for your child
Explore more Paediatric Spasticity Resources

Explore more Paediatric Spasticity Resources

Browse

To access relevant information about Paediatric Spasticity, please choose one of the following options:

Adverse events should be reported.
Reporting forms and information can be found at www.hpra.ie or e-mail medsafety@hpra.ie.
The HPRA can also be contacted on +353 16764971. Adverse events should also be reported to Ipsen via email at pharmacovigilance.uk-ie@ipsen.com or phone on +353 1 8098256.

Reporting of side effects:
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly to the HPRA. Reporting forms and information can be found at www.hpra.ie or email medsafety@hpra.ie. Adverse events should also be reported to Ipsen via email at pharmacovigilance.uk-ie@ipsen.com or phone on +353 1 8098256. By reporting side effects, you can help provide more information on the safety of this medicine.